The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice

IL-6 and related cytokines as the critical lynchpins between inflammation and cancer

(2014) Koji Taniguchi et al.   SEMINARS IN IMMUNOLOGY

Complete Remission Achieved With Single Agent CNTO 328, an Anti–IL-6 Monoclonal Antibody, in Relapsed and Refractory Myeloma

(2013) Ajai Chari et al.   Clinical Lymphoma Myeloma & Leukemia

18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib

(2013) K Duncan et al.   Blood Cancer Journal

Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

(2012) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia

(2012) L. S. Hodge et al.   BLOOD

Pathogenesis of Myeloma

(2011) Kenneth C. Anderson et al.   Annual Review of Pathology-Mechanisms of Disease

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH